We would love to hear your thoughts about our site and services, please take our survey here.
Think about EUA NCYT and what it meant to have a world beating asset, the sp got stuck and drifted at times too but eventually did nearly 100x from low ,unfortunately for them macro circumstances fizzled it out but this can possibly last a lifetime and the amount of lives we save is priceless
Who cares about day to day buys and sells, the fundamental always rerates, they funded recently and literally have a goldmine ready for sale. The biggest risers always backrest and consolidate. This will be in the £s this side of the year IMO
Patience will pay
PSA got approved in the 1980s... the fact that there's been nothing more reliable in use since then speaks volumes, they can charge what they like after 10 years+ of work and they own the patents
Imagine 30,000,000 x £1000
My calculator just broke
The SP will break too, once people start looking at what we have here rather than the buys/sells
All IMO
From previous RNS:
Following the publication of the results involving OBD's technology in the multi-disciplinary NHS PROSTAGRAM study using blood to detect prostate cancer on 6 February 2023, there has been unprecedented levels of interest in and demand for access to the PSE test.
Is this a monopoly
Repost from a previous poster
It's always difficult to get a true market value, but if we look at what we know
Analysts at Shore Capital said: “There are approximately 47 million men in the relevant 50-80 age range in the key US market and 25 million PSA tests per year, and a further 10 million men in the UK. The medical need for an improved test is clear.
I saw a video posted on here where the company stated the product would cost around £100 each.
57,000,000 x £100 = 5.7 billion.
Divide that by the share issue you're looking at £41 a share. Admittedly this is a very simple and quite frankly overly optimistic analysis, but it gives us some indication.
Wouldn't say 57m but assuming 50% get tested as per the numbers, its closer to 30m, this is just for USA and UK only
Assuming a small margin of even £20 thats £600m on a conservative PE of 5, thats £3bn/250m (going to allow for some ramp up dilution although we've just raised recently) shares in issue , thats £12 per share upside on a conservative basis.
The less conservative side you're looking at extraordinary numbers.
Probably the most undervalued share in the entire market right now and a gamechanger for men's health.
Not to mention this is only ONE arm of the platform.
Enjoy the re-rate, wouldn't be surprised at all to see a few £s this side of the year
All IMO DYOR
No point worrying about a few penny swings here and there even after a few hundred % rise
This test alone is worth £2-3 on the SP and the platform will be worth a couple of billion
Just sit back and let it rerate, 30m tests a year at what even £30 profit is £900m…. Mcap 60m lol
All IMO
gonna try an ultra conservative *** packet valuation
30m per year, assuming £30 profit per test = £900m profit per annum, on a 3x p/e = £2.7bn/ 200m shares
£1.3bn mcap = £6-7 sp
extraordinary upside
all imo
Isn't the question to be asked, if there is something better out there why have we been using inaccurate PSA tests for god knows how long?
Do we have a monopoly here?
Well Im' trying to be conservative we don't know margins nor manufacturing capacity but a 54% PSA test is kind of pointless so these will be sold in conjunction with every single one, and they go for around £70+ ish privately, there's up to £2.1bn in revenue to be had annually
then there's the question of margins and capacity, but what's certain is that it's a complete gamechanger in early diagnosis
How do you even put a price on that?
All IMO
What folks don't realise is that even at just 1$ per barrel at 962m MID CASE it gives us 80p per share
There's another 500m or so in the 2nd IER, drilling starts soon and they're targeting 5-10$ per barrel
These are astronomical numbers as mentioned many times before, should really be £1-£2 atm
All IMO